Last reviewed · How we verify
Cytokine-Induced Killer Cells
Cytokine-Induced Killer (CIK) cells are ex vivo expanded autologous T lymphocytes that recognize and kill tumor cells through both MHC-restricted and non-restricted pathways.
Cytokine-Induced Killer (CIK) cells are ex vivo expanded autologous T lymphocytes that recognize and kill tumor cells through both MHC-restricted and non-restricted pathways. Used for Advanced solid tumors (phase 3 development), Hematologic malignancies.
At a glance
| Generic name | Cytokine-Induced Killer Cells |
|---|---|
| Also known as | CIK, CIK cells, DC-CIK and CIK, cytokine induced killer cells |
| Sponsor | The First People's Hospital of Changzhou |
| Drug class | Cell therapy; autologous T cell therapy |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CIK cells are generated by culturing patient-derived peripheral blood mononuclear cells with interferon-gamma, anti-CD3 antibodies, and interleukin-2 to expand a population of CD3+CD56+ cells. These cells combine the tumor-targeting specificity of T cells with the broad cytotoxic capability of natural killer cells, enabling recognition of tumor-associated antigens and direct killing of malignant cells.
Approved indications
- Advanced solid tumors (phase 3 development)
- Hematologic malignancies
Common side effects
- Fever
- Chills
- Fatigue
- Infusion-related reactions
- Cytokine release syndrome
Key clinical trials
- CIML NK Cells With Venetoclax for AML (PHASE1)
- Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer (PHASE1)
- CIML NK Cell in Head & Neck Cancer (PHASE1)
- CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction (NA)
- Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML) (PHASE1, PHASE2)
- A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia (PHASE1)
- Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma (EARLY_PHASE1)
- Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer. (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cytokine-Induced Killer Cells CI brief — competitive landscape report
- Cytokine-Induced Killer Cells updates RSS · CI watch RSS
- The First People's Hospital of Changzhou portfolio CI